Anticonvulsant Drug Development Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah 84108, USA.
Epilepsia. 2013 Aug;54 Suppl 4(0 4):24-34. doi: 10.1111/epi.12296.
This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers.
本报告总结了国际抗癫痫联盟（ILAE）/美国癫痫协会（AES）工作组联合会议抗癫痫治疗工作组在伦敦（伦敦会议）的讨论。我们在这里回顾了目前对成人和儿童癫痫的难治性癫痫现有模型的药理学特征的了解。此外，我们还讨论了美国国立神经病学与卒中研究院（NINDS）资助的抗惊厥药物筛选计划（ASP）如何发展，以纳入适当的动物模型，寻找可能具有足够新颖性以进行进一步药物开发的分子。我们还简要讨论了为实现使所有患者停止癫痫发作的目标，今后需要做些什么，呼吁资助机构、制药行业和基础研究人员采取行动。
